


What is claimed is:

1. A compound of formula I:



I

or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof,

wherein:

R^1 is selected from H, a halogen, and a methyl optionally substituted with one or more fluorines;

R^2 , R^3 , R^4 , and R^5 are each independently selected from H, a halogen, an amide, a sulfonamide, a C_1 - C_5 alkyl optionally substituted with one or more halogens, a C_2 - C_5 alkenyl optionally substituted with one or more halogens, a C_2 - C_5 alkynyl optionally substituted with one or more halogens, a C_1 - C_4 alkoxy optionally substituted with one or more halogens and a C_1 - C_4 thioalkyl optionally substituted with one or more halogens, a C_2 - C_4 thioalkenyl optionally substituted with one or more halogens, and a C_2 - C_4 thioalkynyl optionally substituted with one or more halogens; or


R^2 and R^3 taken together form a 3 to 8 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines; or

R^3 and R^4 taken together form a 5 to 6 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines; or

R^4 and R^5 taken together form a 5 to 6 membered carbocyclic or heterocyclic ring, optionally substituted with one or more fluorines;

R^6 is selected from H, a C_1 - C_3 alkyl optionally substituted with one or more halogens, a C_2 - C_3 alkenyl optionally substituted with one or more halogens, and a C_2 - C_3 alkynyl optionally substituted with one or more halogens;

R^7 is selected from CH_2OH , CHO , $COOH$ and a group of formula (a):



wherein R^8 and R^9 are each independently selected from H, OH and a methyl optionally substituted with one or more fluorines;

n is 1, 2 or 3;

X is O, NR^{10} or S; and

R^{10} is selected from H, a C_1 - C_3 alkyl optionally substituted with one or more halogens, a C_2 - C_3 alkenyl optionally substituted with one or more halogens, and a C_2 - C_3 alkynyl optionally substituted with one or more halogens.

2. A compound according to claim 1, wherein:

R^1 is selected from H and a C_1 - C_4 alkyl optionally substituted with one or more halogens;

R^6 is selected from H and a C_1 - C_3 alkyl group optionally substituted with one or more halogen;

R^2 , R^3 , R^4 and R^5 are each independently selected from H, a halogen, a C_1 - C_3 alkyl optionally substituted with one or more halogens, a C_2 - C_3 alkenyl optionally substituted with one or more halogens, a C_2 - C_3 alkynyl optionally substituted with one or more halogens, a C_1 - C_3 alkoxy optionally substituted with one or more halogens, a C_1 - C_3

thioalkyl optionally substituted with one or more halogens, a C₂-C₃ thioalkenyl optionally substituted with one or more halogens, and a C₂-C₃ thioalkynyl, optionally substituted with one or more halogens; or

R² and R³ taken together form a 4 to 7 membered carbocyclic or heterocyclic ring optionally substituted with one or more halogens; or

R³ and R⁴ taken together form a 5 to 6 membered carbocyclic or heterocyclic ring optionally substituted with one or more halogens.

3. A compound according to claim 2, wherein:

R², R³, R⁴ and R⁵ each independently is selected from the group H, C₁-C₂ alkyl optionally substituted with one or more halogens, a C₂ alkenyl group optionally substituted with one or more halogens, an C₁-C₂ alkoxy group optionally substituted with one or more halogens, and a C₁-C₂ thioalkyl group optionally substituted with one or more halogens; or

R² and R³ taken together form a 5 to 6 membered carbocyclic or ring optionally substituted with one or more fluorines; or

R³ and R⁴ taken together form a 5 to 6 membered carbocyclic ring optionally substituted with one or more fluorines; or

R⁴ and R⁵ taken together form a 5 to 6 membered carbocyclic ring optionally substituted with one or more fluorines.

4. A compound according to claim 1, wherein:

R² and R³ are each independently selected from H and methyl; or

R^2 and R^3 taken together from a 3 to 8 membered carbocyclic ring.

5. A compound according to claim 1, wherein:

R^3 and R^4 are each independently methyl; or

R^3 and R^4 taken together from a 3 to 8 membered carboxylic ring.

6. A compound according to claim 1, wherein R^1 , R^2 , R^3 , and R^4 are each independently selected from H and a methyl optionally substituted with one or more fluorines.

7. A compound according to any one of claims 2, 3, 4 and 6, wherein R^5 and R^6 are each

H.

8. A compound according to claim 7, wherein:

R^7 is $C(R^8)(R^9)(OOH)$,

wherein R^8 and R^9 are each independently selected from H and a methyl optionally substituted with one or more fluorines.

9. A compound selected from: 4-(2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)phenylacetic acid, 4-(8,9-dimethyl-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(8,9-cyclopentano-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(9,10-benzo-2,3,4a,5,6,10b-hexahydropyrano[3,2-c]quinolin-5-yl)benzoic acid, 4-(2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)benzoic acid, 4-(2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)phenylacetic acid, and 4-(9,10-benzo-2,3,3a,4,5,9b-hexahydrofuro[3,2-c]quinolin-4-yl)benzoic acid.

10. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 1.
11. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 2.
12. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 3.
13. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 4.
14. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 5.
15. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 6.
16. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 7.
17. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 8.
18. A pharmaceutical agent comprising a pharmaceutically acceptable carrier and a compound of claim 9.
19. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 1.
20. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity,

cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 2.

21. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 3.

22. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 4.

23. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 5.

24. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 6.

25. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 7.

26. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity,

cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 8.

27. A method of treating a patient having a disease or condition selected from the group of syndrome X, non-insulin dependent diabetes mellitus, cancer, obesity, cardiovascular disease and dyslipidemia comprising administering to said patient a pharmaceutically effective amount of a compound of claim 9.